COMP <GO>
BMRN vs ELAN // 10Y YIELD & FRED MACRO BETA
BioMarin Pharmaceutical Inc. (NASDAQ) VS. Elanco Animal Health Incorporated (NYSE) • 15-METRIC TALLY: BMRN 9
— ELAN 3
▲ 10Y YIELD & FRED MACRO BETA LEADER: ELAN
LAST: $57.44 (-1.83%) • MKT CAP: $11.33B
macro-sensitivity
0.95
LAST: $24.10 (+4.51%) • MKT CAP: $11.52B
macro-sensitivity
0.96
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BMRN VS. ELAN)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BMRN | ELAN | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 77.70% | 55.00% | +22.70 | BMRN | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 6.00% | -2.50% | +8.50 | BMRN | /roic <GO> |
| EV/EBITDA & P/E Valuation | 21.0x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 6.51% | 2.45% | +4.06 | BMRN | /fcf-yield <GO> |
| Operating Margin | 12.70% | -6.00% | +18.70 | BMRN | /operating-margins <GO> |
| Net Profit Margin | 10.80% | -4.90% | +15.70 | BMRN | /net-margins <GO> |
| Revenue Growth (YoY) | 12.90% | 6.20% | +6.70 | BMRN | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 5.57 | 1.24 | +4.33 | BMRN | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | BMRN | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 54.4 | 51.9 | +2.50 | BMRN | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta ACTIVE | 0.95 | 0.96 | -0.01 | ELAN | /macro-sensitivity <GO> |
| Forward P/E Multiple | 26.8x | 20.0x | +6.80 | ELAN | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $11.33B | $11.52B | -$195.3M | ELAN | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BMRN REV | ELAN REV | BMRN GROSS % | ELAN GROSS % | BMRN FCF | ELAN FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $3.22B | $4.71B | 77.7% | 55.0% | $725.0M | $284.0M |
| FY 2024 | $2.85B | $4.44B | 79.7% | 54.9% | $487.4M | $394.0M |
| FY 2023 | $2.42B | $4.42B | — | — | $50.4M | $72.2M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BMRN // BETA 0.95
ELAN // BETA 0.96